Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A Phase I-IIa Study of Dose-escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma

Proposed period of release:
01/08/2006 to 31/12/2008

Name of the Institute(s) or Company(ies)
Uppsala University, Division of Clinical Immunology, Uppsala., Sweden;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
AdCD40L is consisting of a recombinant adenovirus group C serotype 5 E1E3 deleted vector expressing the human CD40L (CD154) gene under controll of a promoter derived from RousSarcoma Virus (RSV) (Leimig et al Human Gene Ther 7:1233-1239, 1996; Takahashi et al Hum Gene Ther 12:659-670, 2001).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Adenovirus human serotype 5 (Ad5)Mastadenovirushuman adenovirussubgroup Cserotype 5-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known